Avoidant or Restrictive Food Intake Disorder Symptoms in Adults With Systemic Sclerosis: A Nationwide Study in Spain

Author:

Alcala‐Gonzalez Luis G.1ORCID,Burton‐Murray Helen2,Atkins Micaela2,Guillen‐del‐Castillo Alfredo3ORCID,Malagelada Carolina4ORCID,Hughes Michael5ORCID,McMahan Zsuzsanna H.6ORCID,Simeón‐Aznar Carmen P.3ORCID

Affiliation:

1. Digestive System Research Unit, Digestive Diseases Department Vall d'Hebron University Hospital Barcelona Spain

2. Massachusetts General Hospital and Harvard Medical School Boston

3. Systemic Autoimmune Diseases Unit, Internal Medicine Department Vall d'Hebron University Hospital Barcelona Spain

4. Digestive System Research Unit, Digestive Diseases Department, Vall d'Hebron University Hospital, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas, and Department of Medicine Universitat Autònoma de Barcelona Barcelona Spain

5. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester and Manchester Academic Health Science Centre, Manchester, UK, and Northern Care Alliance NHS Foundation Trust, Salford Care Organisation Salford UK

6. University of Texas Health Science Center at Houston

Abstract

ObjectivePatients with systemic sclerosis (SSc) may restrict food intake to manage their symptoms (particularly gastrointestinal [GI]). Whether some patients may develop nutritional and/or quality‐of‐life impairments indicative of an eating disorder, avoidant or restrictive food intake disorder (ARFID), is unknown. We aimed to (1) identify the prevalence and characteristics of ARFID symptoms in patients with SSc and (2) explore the relationship among ARFID symptoms, GI symptom burden, and health‐related quality of life.MethodsIn a cross‐sectional internet survey nationwide in Spain, patients with SSc completed the Spanish Nine‐Item ARFID Screen and assessments of gastrointestinal symptom burden (University of California Los Angeles Scleroderma Clinical Trial Consortium GI tract 2.0 [UCLA SCTC GIT 2.0]) and health‐related quality of life (12‐item Short Form Survey [SF‐12]).ResultsOf 200 patients with SSc, 99 patients (49.5%) screened positive for ARFID. Just over half of those who screened positive for ARFID (n = 53) screened positive based on having a fear of aversive consequences around eating (eg, GI discomfort). A positive ARFID screen was associated with a greater frequency of self‐reported enteral nutrition, weight loss, and self‐initiated (vs provider‐monitored) diet restrictions. ARFID symptoms were moderately associated with worse GI symptom severity by UCLA GIT 2.0 total score (r = 0.408, P < 0.001) but not for the reflux subscale (r = 0.058, P = 0.420) and constipation subscale (r = 0.090, P = 0.209) and with worse health‐related quality of life in all domains and both the physical and mental components of the SF‐12 (all P < 0.05).ConclusionARFID symptoms were relatively common in patients with SSc. Future research is needed to identify when a positive screen for ARFID reflects an adaptive response to disease or pathologic restriction indicative of ARFID warranting behavioral treatment.

Funder

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3